含苯并噻唑基乳糖基胍的合成

2,3,6,2',3',4',6'-七-O-乙酰基-β-乳糖基异硫氰酸酯(1)分别与2-氨基-4/6-取代苯并噻唑2a～2e反应, 制得糖基硫脲3a～3e, 将其在HgCl₂作用下与伯胺反应, 制得一系列新化合物N-烷基/芳基-N'-(4/6-取代-苯并噻唑-2-基)-N'-(2,3,6,2',3',4',6'-七-O-乙酰基-β-乳糖基)胍4～6. 然后, 在CH₃ONa/CH₃OH作用下, 脱乙酰基得含苯并噻唑基的乳糖基胍类化合物7～9. 所有新化合物的结构均经IR, ¹H NMR, MS谱和元素分析证实, 所得产物均为b-构型. 对代表性化合物的生物活性测试结果表明, 乳糖基胍类化合物对HIV-1蛋白酶、血管紧张素转化酶(ACE)的抑制活性较差.     

合欢皮中两个新八糖苷的分离鉴定和活性研究

从合欢皮95%乙醇提取物中分离得到2个新的八糖苷(1, 2), 经化学方法与光谱分析将其结构鉴定为3-O-[β-D-吡喃木糖基-(1→2)-α-L-吡喃阿拉伯糖基-(1→6)-β-D-吡喃葡萄糖基]-21-O-[(6S)-2-反式-2-羟甲基-6-甲基-6-O-β-D-吡喃鸡纳糖基-2,7-辛二烯酸基]-金合欢酸-28-O-β-D-吡喃葡萄糖基-(1→3)-[α-L-呋喃阿拉伯糖基-(1→4)]-α-L-吡喃鼠李糖基- (1→2)-β-D-吡喃葡萄糖基酯(1)和3-O-[β-D-吡喃木糖基-(1→2)-α-L-吡喃阿拉伯糖基-(1→6)-β-D-2-去氧-2-乙酰氨基吡喃葡萄糖基]-21-O-[(6S)-2-反式-2-羟甲基-6-甲基-6-O-β-D-吡喃鸡纳糖基-2,7-辛二烯酸基]-金合欢酸-28-O-β-D-吡喃葡萄糖基-(1→3)-[α-L-呋喃阿拉伯糖基-(1→4)]-α-L-吡喃鼠李糖基-(1→2)-β-D-吡喃葡萄糖基酯(2), 分别命名为合欢皂苷J₂₅ (1, Julibroside J₂₅)和合欢皂苷J₂₂ (2, Julibroside J₂₂). 1和2在体外对4种人癌细胞增殖有明显的抑制作用.     

N-烷基/芳基-N'-(4-芳基噻唑-2-基)-N"-糖基胍的合成及生物活性研究

2,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖基异硫氰酸酯(1)与2-氨基-4-取代苯基噻唑(2a～2b)反应, 生成糖基硫脲衍生物3a～3b, 再在伯胺存在下经氯化汞脱硫, 得到一系列新的N-烷基/芳基-N'-(4-芳基噻唑-2-基)-N"-糖基胍类化合物(4a～4e, 5a～5e). 所有新化合物的结构均经IR, ¹H NMR, MS谱和元素分析证实, 所得产物均为β-构型. 生物活性测试结果表明, 化合物4b和5d对HIV-1 PR表现出了较高的抑制活性.     

氨基糖衍生物二丁基锡配合物的合成、结构表征和生物活性

分别由2-[(2Z)-3-羧基-1-氧代-2-丙烯基]氨基-2-脱氧-1,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖(1a), 2-[(2-羧基苯甲酰基)氨基]-2-脱氧-1,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖(2a)和氧化二正丁基锡反应合成了两个新化合物双-{2-[(2Z)-3-羧基-1-氧代-2-丙烯基]氨基-2-脱氧-1,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖}-二正丁基锡酯(1)和双-{2-[(2-羧基苯甲酰基)氨基]-2-脱氧-1,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖}-二正丁基锡酯(2), 并经红外光谱、核磁共振(¹H, ¹³C NMR)、质谱初步确定了其结构. 体外抗肿瘤活性结果表明, 化合物1对人肺癌细胞株A-549和人肝癌细胞株BEL-7402的细胞毒活性显示为强效; 而对小鼠白血病细胞株P388和人白血病细胞株HL-60的细胞毒活性为弱效. 化合物2对肿瘤细胞株HL-60, A-549和BEL-7402具有强效的细胞毒活性; 而对肿瘤细胞株P388的作用则为弱效. 克隆基因分析表明化合物1和2在3.82×10^－6 和 3.02×10^－6 mol/L均具有造血细胞毒性.     

Lewis酸催化下2-(2,3,5-三-O-苯甲酰基-D-呋喃核糖)-1,4-氢醌的合成

在不同Lewis酸催化下, 使用1,4-二苯酚和1-O-乙酰基-2,3,5-三-O-β-D-呋喃核糖进行反应, 以较高产率合成了α和β型芳香呋喃糖苷, 并利用¹H-¹H NOESY谱对2-(2,3,5-三-O-苯甲酰基-D-呋喃核糖)-1,4-氢醌(5)的立体构型进行了表征. 应用无水AlCl₃, ZnCl₂和BF₃•Et₂O等Lewis酸催化剂仅得到β型氧糖苷3, 应用TiCl₄得到β型氧糖苷3以及α和β型碳糖苷的混合物5, 而应用SnCl₄则得到α和β型碳糖苷5.     

黑龙骨中两个新强心苷的结构鉴定

系统研究黑龙骨Periploca forrestii Schltr.中的化学成分, 利用各种色谱技术进行分离, 得到2个新类型的强心苷,黑龙骨苷甲和乙. 并通过化学和光谱方法(MS, ¹H, ¹³C NMR和2D NMR)鉴定其结构为: 5β-羟基-8,14β-环氧-强心 甾- 20(22)-烯-3-O-β-D-磁麻吡喃糖苷(1)和5β-羟基-8,14β-环氧-强心甾-20(22)-烯-3-O-β-D-葡萄吡喃糖基-(1→4)-β-D-磁麻吡喃糖苷(2).     

槲树叶中的5种酚性成分

从槲树叶Quercus dentata Thunb中分离纯化得到五种酚性成分. 通过理化性质分析和光谱解析等手段确定其化学结构分别为: 2-新橙皮糖基-2,6-二羟基苯甲酸苯甲酯(1), 龙胆酸5-O-(6-O-没食子酰基)--D-吡喃葡萄糖苷(2), 3,5,7-三羟基色原酮-3-O--D-吡喃葡萄糖苷(3), 没食子酸(4), 儿茶素(5), 其中化合物1和3为新化合物.     

香菇多糖核心片段六糖的合成研究

以已知的2,3,4,6-四-O-苯甲酰基--D-葡萄吡喃糖-(13)-[2,3,4,6-四-O-苯甲酰基-β-D-葡萄吡喃糖-(16)]-2,4- 二-O-乙酰基-β-D-葡萄吡喃糖-(13)-2,4,6-三-O-乙酰基-α-D-葡萄吡喃糖三氯乙酰亚胺酯(2)为供体, 以2-O-苯甲酰 基-4,6-O-苄叉基-α-D-葡萄吡喃糖烯丙基苷(4)作为受体, 立体专一性地偶联得到β-1,3连接的五糖5. 五糖5酸解脱去4,6-苯亚甲基基后与2,3,4,6-四-O-苯甲酰基-α-D-葡萄吡喃糖三氯乙酰亚胺酯(7)偶联, 区域和立体专一性地得到全保护的β-1,3主链β-1,6支链的六糖8. 六糖8脱保护后得到目标化合物香菇多糖核心片段六糖9. 发展了合成该类化合物的一种新方法.     

巢式十一顶铂硼烷簇合物的合成与晶体结构

[PtCl₂(PPh₃)₂]与B₁₀H₁₀^2－在异丙醇中回流反应, 得到3个巢式十一顶铂十硼烷簇合物: [(PPh₃)₂PtB₁₀H₁₁-9-O-i-Pr] (1), [(PPh₃)₂PtB₁₀H₁₀-8,10-(O-i-Pr)₂] (2)和[(PPh₃)₂PtB₁₀H₁₁-8-O-i-Pr] (3). 簇合物1～3都具有PtB₁₀多面体骨架结构, 其中Pt原子位于敞开的PtB₄面上, 且与4个B原子成键, 每个Pt原子还与2个PPh₃基团中的P原子成键. 将溶剂热合成的方法引入到硼簇合物的合成中并进行同一反应, 得到2个B₁₀H₁₀^2－降解的巢式十一顶双铂九硼烷簇合物: [(PPh₃)₂(μ-PPh₂)Pt₂B₉H₆-3,9,11-(O-i-Pr)₃] (4)和[(PPh₃)₂(μ-PPh₂)Pt₂B₉H₆-3,9-(O-i-Pr)₂-11-Cl] (5). 簇合物4和5都具有Pt₂B₉多面体骨架结构, 2个Pt原子位于敞开的Pt₂B₃面上的相邻位置, 且由一个PPh₂基团桥连, 每个Pt原子还与3个B原子和一个PPh₃基团中的P原子成键. 通过红外光谱、元素分析、X射线单晶衍射对5个簇合物进行了结构表征.     

贫电子环丙烷衍生物与2-巯基苯骈噻唑的反应研究

贫电子环丙烷衍生物1以精制四氢呋喃为溶剂, 与2-巯基苯骈噻唑(2)封管加热反应, 得到产物3和4. 产物3经IR, MS, ¹H NMR, ¹³C NMR和元素分析等数据确定其结构为: (R)-β-取代-(R)-γ-(2-巯基)苯骈噻唑基-γ-对位取代苯基丁酸或(S)-β-取代-(S)-γ-(2-巯基)苯骈噻唑基-γ-对位取代苯基丁酸(3); 产物4通过IR, MS, ¹H NMR, ¹³C NMR, 2D-NOESY谱和元素分析等数据确定其结构为: 反式-β-取代-γ-对位取代苯基-3-丁烯酸(4). 对生成产物的机理也进行了推测.     

胍基木吡喃糖苷的合成及其抗HIV蛋白酶活性

2,3,4-三-O-乙酰基-b-D-木吡喃糖基异硫氰酸酯1与2-氨基-4/6-取代-苯并噻唑2a～2e反应, 生成糖基硫脲衍生物3a～3e, 再在伯胺存在下经氯化汞脱硫, 得到一系列新的胍基木吡喃糖苷类化合物4a～4e, 5a～5e, 6a～6e, 7a～7e, 所有新化合物的结构均经IR, ¹H NMR, MS谱和元素分析证实, 所得产物均为β-构型. 生物活性测试结果表明, 化合物4c, 5b, 6b～6d, 7b等对HIV-1蛋白酶表现出了较高的抑制活性.     

地奥心血康中的两个新甾体皂苷

通过正相和反相硅胶柱层析, 从地奥心血康药粉的正丁醇萃取物中分离纯化出2个微量的新甾体皂苷, 通过MS和NMR(包括HMQC, HMBC和NOESY)等波谱解析, 结合化学降解分析将其结构鉴定为3β,26-二醇-25(R)-Δ^5,20(22)-二烯-呋甾-26-O-β-D-吡喃葡萄糖苷(1)和26-O-β-D-吡喃葡萄糖基-3β,20α,26-三醇-25(R)-Δ^5,22-二烯-呋甾-3-O-α-L-吡喃鼠李糖基(1→2)-[α-L-吡喃鼠李糖基(1→4)]-β-D-吡喃葡萄糖苷(2).     

Lewisx五糖的有效合成: 发展DC-靶向疫苗的有效分子

将选择性保护的乳糖二醇与Lewis^x三糖在N-碘代丁二酰亚胺(NIS)/TfOH催化下高立体、高区域选择性糖苷化得Lewis^x五糖, 后者脱保护后获得目标五糖, 总收率67.7%. 化合物结构经NMR, MS和元素分析确证.     

Synthesis of Four Spacer-Containing Trisaccharides with the 4-0-(β-L-Rhamnopyranosyl)-D-glucopyranose Unit in Common,Representing Fragments of Capsular Polysaccharides from Streptococcus Pneumoniae Types 2, 7F, 22F,and 23F

Abstract

The synthesis is reported of 3-aminopropyl 3-O-[4-O(β-L-rhamnopyranosyl)-β-D-glucopyranosyl]-α-L-rhamnopyranoside (34), 3-aminopropyl 2-acetamido-3-O-[4-0-(β-L-rhamnopyranosyl)-β-D-glucopyranosyl]-2-deoxy-β-D-galactopyranoside (37), 3-aminopropyl 3-O-[4-O-(β-L-rhamnopyranosyl)-α-D-glucopyranosyl]-α-D-galactofuranoside (41), and 3-aminopropyl 4-O-[4-O-(β-L-rhamnopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranoside (45). These are spacer-containing fragments of the capsular polysaccharides of Streptococcus pneumoniae type 2, 7F, 22F, and 23F, respectively, which are constituents of Pneumovax^© 23. 2,3,4-Tri-O-benzyl-α-L-rhamnopyranosyl bromide was coupled to l,6-anhydro-2,3-di-(O-benzyl-β-D-glucopyranose (3). Opening of the anhydro ring, removal of AcO-1, and imidation of l,6-anhydro-2,3-di- O-benzyl-4-O-(2,3,4-tri-O-benzyl-β-L-rhamnopyranosyl)-β-D-glucopyranose (4β) afforded 6-O-acetyl-2,3-di-O-ben-zyl-4-O-(2,3,4-tri- O-benzyl-β-L-rhamnopyranosyl)-αβ-D-glucopyranosyl trichloroacet-imidate (7αβ). Condensation of 7αβ with 3-N-benzyloxycarbonylaminopropyl 2-O-ben-zyl-5,6-O-isopropylidene-α-D-galactofuranoside (26), followed by deprotection gave 41 Opening of the anhydro ring of 4 p followed by debenzylation, acerylauon, removal of AcO-1, and imidation yielded 2,3,6-tri-(9-aceryl-4-O-(2,3,4-tri-0-acetyl-P-L-rharnnopyran-.-osyl)-α-D-glucopyranosyl trichloroacetimidate (11). Condensation of 11 with 3-N-bcn-zyloxycarbonylaminopropyl 2,4-di-O-benzyl-α-L-rhamnopyranoside (18), with 3-N-bcn-zyloxycarbonylaminopropyl 2-acetamido-4,6-O-benzylidene-2-deoxy-β-D-galactopyran-oside (21), or with 3-N -benzyloxycarbonylaminopropyl 2-O-acetyl-3-O-allyl-6-O-benzyl-β-D-galactopyranoside (31), followed by deprotection afforded 34, 37, and 45, respectively.     

Studies on the Thioglycosides of N-Acetyl-Neuraminic Acid 8: Synthesis of S-(α-Sialyl)-(2→ 6)-β-Hexopyranosyl and -(2→ 6')-β-Lactosyl Ceramides Containing β-Thioglycosidically Linked Ceramide

ABSTRACT

Coupling of the sodium salt of S-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-galacto-2-nonulopyranosylonate)-(2→'6)-2,3,4-tri-O-acetyl-1,6-dithio-β-D-glucopyranose (5), -β-D-galactopyranose (8), or S-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate)-(2→'6)-O-(2,3,4-tri-O-acetyl-6-thio-β-D-galactopyranosyl)-(1→'4)-2,3,6-tri-O-acetyl-1-thio-β-D-glucopyranose (12), which were prepared from the corresponding 1-hydroxy compounds, 1, 2, and 9, via 1-chlorination, displacement with thioacetyl group, and S-deacetylation, with (2S,3R,4E)-2-azido-3-O-benzoyl-1-O-(p-toluenesulfonyl)-4-octadecene-1,3-diol (13), gave the corresponding β-thioglycosides 14, 18 and 22, respectively in good yields. The β-thioglycosides obtained were converted, via selective reduction of the azide group, condensation with octadecanoic acid, and removal of the protecting groups, into the title compounds.     

短柄雪胆中的三萜葫芦素及其皂苷

从短柄雪胆的块根中分离得到了14个三萜葫芦素类化合物. 经波谱分析及化学方法鉴定了它们的结构, 其中有新化合物5个, 分别命名为短柄雪胆苷A～E (1～5), 以及肉花雪胆苷元A (6), 藤三七雪胆苷R8 (7), 肉花雪胆苷I (8), 肉花雪胆苷II (9), 肉花雪胆苷III (10), 雪胆甲素(11), 雪胆乙素(12), 雪胆甲素苷(13), 藤三七雪胆苷R1 (14)等9个已知化合物. 6是首次从自然界中得到的化合物.     

Synthetic Studies on Sialoglycoconjugates 59: Total Synthesis of Tumor-Associated Ganglioside,Sialyl Le

Abstract

The first total synthesis of tumor-associated glycolipid antigen, sialyl Le^a, is described. Methylsulfenyl bromide-silver triflate-promoted coupling of 2-(trimethylsilyl)ethyl O-(2-acetamido-6-O-benzyl-2-deoxy-β-d-glucopyranosyl)-(1→3)-O-(2,4,6-tri-O-benzyl-β-d-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-d-glucopyranoside (2) with methyl O-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-d-glycero-α-d-galacto-2-nonulopyranosylonate)-(2→3)-2,4,6-tri-O-benzoyl-1-thio-β-d-galactopyranoside (3) afforded the pentasaccharide 4a and 5a in good yields. Glycosylation of 4a with methyl 2,3,4-tri-O-benzyl-1-thio-β-l-fucopyranoside (6) by use of N-iodosuccinimide (NIS) — trifluoromethanesulfonic acid (TfOH) as a promoter, gave the desired hexasaccharide 7. Compound 7 was converted into the α-trichloroacetimidate 10, via reductive removal of benzyl groups, O-acetylation, removal of the 2-(trimethylsilyl)ethyl group, and treatment with trichloroacetonitrile, which, on coupling with (2S, 3R,4E)-2-azido-3-O-benzoyl-4-octadecene-1, 3-diol (11), gave the β-glycoside 12. Finally, 12 was transformed, via selective reduction of the azide group, coupling with octadecanoic acid, O-deacylation, and hydrolysis of the methyl ester group, into the title ganglioside 15 in good yield.     

Synthetic Studies on Sialoglycoconjugates 104: Synthesis of Kdn-Lewis X Ganglioside Analogs Containing Modified Reducing Terminal and L-Rhamnose in Place of L-Fucose 1 2

Abstract

KDN-Le^x ganglioside analogs (10, 13, 16 and 19) containing the modified reducing terminal and L-rhamnose in place of L-fucose have been synthesized. Glycosidation of methyl 2,3,4-tri-O-benzyl-1-thio-α-L-rhamnopyranoside (1) with 2-(trimethylsilyl)ethyl O-(2-acetamido-4,6-O-benzylidene-2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(2,4,6-tri-O-benzyl-α-D-galacopyranoside (2), followed by reductive ring opening of the benzylidene acetal, gave 2-(trimethylsilyl)ethyl O-(2,3,4-tri-O-benzyl-α-L-rhamnopyranosyl)-(1→3)-O-(2-acet-amido-6-O-benzyl-2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(2,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (4). The tetrasaccharide 4 was coupled with methyl O-(methyl 4,5,7,8,9-penta-O-acetyl-3-deoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate)-(2→3)-2,4,6-tri-O-benzoyl-1-thio-β-D-galactopyranoside(5), using dimethyl(methylthio)sulfonium triflate (DMTST), to give the hexasaccharide 6, which was converted into compound 11 in the usual manner. Compounds 8 and 11 were transformed, via bromination of the reducing terminal, radical reduction, O-deacylation and saponification of the methyl ester, into the desired KDN-Le^x hexasaccharides (10, 13). On the other hand, glycosylation of 2-(tetradecyl)hexadecanol with α-trichloroacetimidates 14 and 17, afforded the target ganglioside analogs 16 and 19.